-
FK866 (APO866) Workflows for NAD and AML
2026-09-04
Build reproducible FK866 experiments around NAD depletion, ATP loss, mitochondrial membrane depolarization, and caspase-independent cell death. This practical guide connects NAMPT inhibition with hematologic cancer research while showing how findings from PARP inhibitor resistance research can inform assay design without overstating translational evidence.
-
ABT-737 as a Mitochondrial Apoptosis Probe
2026-09-04
ABT-737 is a BCL-2 protein inhibitor that can do more than induce apoptosis: it can help distinguish mitochondrial execution from upstream death signaling. This article integrates ABT-737 with the 2025 RNA Pol II degradation study to develop a more rigorous assay strategy for cancer research.
-
GABAAR Surface Trafficking and ER Quality Control
2026-09-03
The reference study identifies a conserved extracellular sequence next to the first transmembrane domain that controls GABAAR processing and delivery to the cell surface. Mutational, chaperone-association, degradation-inhibition, and structural-modeling results indicate that this region helps stabilize calnexin-dependent quality control in the endoplasmic reticulum without being required for receptor subunit assembly.
-
BFH772 (VEGFR2 inhibitor): Workflow Guide
2026-09-03
BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled studies of VEGFR2-mediated angiogenic signaling in biochemical, cellular, and tumor-model workflows. Its water insolubility requires organic-solvent formulation and vehicle-matched controls, so it is not appropriate for protocols that require aqueous dosing or broad-spectrum kinase inhibition.
-
Chloroquine and Everolimus in Melanoma Cell Death
2026-09-02
The 2024 study by Ciołczyk-Wierzbicka and colleagues shows that combining chloroquine with the mTOR inhibitor everolimus suppresses melanoma-cell proliferation and promotes apoptosis, while also changing intracellular lipid organization. Its strength is the integration of caspase, DNA-fragmentation, fluorescence, morphology, and lipid-distribution assays rather than reliance on a single cell-death readout.
-
Bobcat339 for TET Inhibition Workflows
2026-09-02
Bobcat339 enables a controlled way to interrogate TET1/TET2 activity, DNA methylation regulation, and downstream gene transcription. This workflow connects biochemical inhibition with multi-omics and osteogenic assays, helping researchers distinguish direct epigenetic effects from secondary cellular stress.
-
Concanavalin A Targets Conserved Coronavirus N-Glycans
2026-09-01
The reference study identifies phylogenetically conserved N-linked glycans near the coronavirus spike S2′ cleavage site as a broad-spectrum antiviral vulnerability. By combining fusion, pseudovirus, authentic-virus, biochemical, and animal models, the authors show that concanavalin A blocks spike activation and coronavirus entry rather than targeting rapidly changing receptor-binding epitopes.
-
TCAIM Control of OGDH and Mitochondrial Metabolism
2026-09-01
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work reveals that mitochondrial proteostasis can directly tune OGDH complex activity and carbohydrate metabolism beyond its established role in protein folding.
-
Imipramine: From Autophagy to Translational Strategy
2026-08-31
A mechanism-first framework for using Imipramine in autophagy, apoptosis, lipidomics, neuroscience, and translational research—while distinguishing established evidence from testable ceramide-centered hypotheses.
-
10058-F4 in c-Myc-Max Mechanistic Assays
2026-08-31
Use 10058-F4 to connect c-Myc-Max disruption with transcriptional, chromatin, cell-cycle, and mitochondrial apoptosis readouts. Its value extends from acute myeloid leukemia research and prostate cancer models to a reference-informed workflow for studying TERT regulation in human pluripotent stem cells.
-
Anastasis After Caspase Activation: Kinome Screen Insights
2026-08-30
A recent preprint introduces a quantitative kinome-inhibitor screening strategy to identify pathways that regulate anastasis, the recovery of cells after potentially lethal effector-caspase activation. The findings implicate adhesion, cytoskeletal remodeling, growth-factor signaling, Rho kinase, and Akt as important determinants of post-caspase survival, while providing a framework for distinguishing recovery-specific effects from general drug toxicity.
-
Protease Inhibitor Cocktail: MS-SAFE 50X
2026-08-29
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue protein extraction, with an AEBSF-free formulation intended for mass spectrometry workflows. It should be validated for each sample matrix and supplemented separately with EDTA when metalloproteinase inhibition is required.
-
NFIA Coordinates Bone Resorption and Formation
2026-08-28
The reference study identifies nuclear factor I/A (NFIA) as a previously unrecognized regulator of bone homeostasis in mesenchymal stem and progenitor cells. By controlling RANKL and SFRP1, NFIA restrains osteoclast support while also limiting osteoblast differentiation, with loss of its anti-resorptive effect producing a net reduction in bone mass accrual.
-
METTL14, DHRS4-AS1, and Ulcerative Colitis
2026-08-28
A 2024 Cell Biology and Toxicology study identifies an m6A-dependent METTL14–DHRS4-AS1–miR-206–A3AR regulatory axis that limits epithelial inflammatory injury in ulcerative colitis models. Its combined cell and animal experiments connect RNA modification with NF-κB activation, apoptosis, and colonic damage, while also defining important limits for translation beyond experimental systems.
-
Ibrutinib (PCI-32765) BTK Research Workflows
2026-08-27
Build reproducible Ibrutinib and PCI-32765 assays for B-cell receptor signaling inhibition, chronic lymphocytic leukemia research, and genotype-aware exploratory studies. This guide combines covalent BTK target engagement with practical formulation, dose-response, washout, and troubleshooting strategies while separating established B-cell applications from ATRX-deficient glioma hypotheses.